Some of the US Food and Drug Administration’s vaccine advisors expressed interest in using Novavax, Inc.’s currently unauthorized protein-based COVID-19 vaccine, NVX-CoV2373, as a booster candidate this fall to help elicit broader protection against new and future SARS-CoV-2 variants.
They pushed the agency to think more broadly about the booster topic than the FDA seemed willing during the 28...